|

rezatapopt Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: PC14586

Pipeline

Phase 1: 2Phase 1/2: 1

Top Sponsors

  • PMV Pharmaceuticals, Inc2
  • M.D. Anderson Cancer Center1

Indications

  • Cancer3
  • TP53 Y220C Mutation1
  • ER/PR(+), Her2(-) Breast Cancer1
  • ER/PR Positive Breast Cancer1
  • TNBC1

Irvine, California1 trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

University of California Irvine Chao Family Comprehensive Cancer Center

Phase 1/2

Denver, Colorado1 trial

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

HealthOne Denver

Phase 1

Houston, Texas1 trial

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

The University of Texas MD Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.